Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pablito Nagpala

Pediatric Endocrinology Long Beach, CA Medical Doctor

NPI 1306820071 CMS profile 330986

2650 Elm Ave, Suite 210, Long Beach, CA 90806

Open in the dashboard

General payments

$10,812

557 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pablito Nagpala of Long Beach, CA is reported in the CMS Open Payments database as having received $10,812 across 557 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,646 92
2024 General $1,675 91
2023 General $1,602 77
2022 General $1,703 96
2021 General $1,423 82
2020 General $960 51
2019 General $1,803 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pablito Nagpala
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Pablito Nagpala were reported at $1,646. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Pablito Nagpala Pediatric Endocrinology median Middle half National median
2019 $1,803 $196 $68–$845 $163
2020 $960 $124 $37–$722 $114
2021 $1,423 $134 $35–$691 $132
2022 $1,703 $177 $47–$726 $149
2023 $1,602 $236 $75–$887 $160
2024 $1,675 $259 $91–$979 $164
2025 $1,646 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,814 79 payments
  2. Novo Nordisk Inc $910 54 payments
  3. Arbor Pharmaceuticals, Inc. $860 49 payments
  4. Ascendis Pharma, Inc. $774 36 payments
  5. Dexcom, Inc. $613 35 payments
  6. Insulet Corporation $583 33 payments
  7. Tandem Diabetes Care, Inc. $556 11 payments
  8. Pfizer Inc. $546 23 payments
  9. Amphastar Pharmaceuticals, Inc. $538 41 payments
  10. Tolmar, Inc. $488 26 payments
  11. Other $3,131 170 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,999 537 payments
  2. Education $453 18 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $300 1 payment
  4. Gift $59 1 payment
Products named General payments · program years 2019–2025
  1. LUPRON DEPOT $1,274 52 payments
  2. SKYTROFA $754 35 payments
  3. Dexcom G6 Transmitter $598 34 payments
  4. Triptodur $562 30 payments
  5. GENOTROPIN $496 21 payments
  6. FENSOLVI $467 27 payments
  7. Omnipod $350 15 payments
  8. BAQSIMI $349 17 payments
  9. SYNTHROID $330 17 payments
  10. t-slim insulin pump $327 2 payments
  11. Other $5,739 309 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

557 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record